Terapias dirigidas en la esclerosis sistémica: una revisión narrativa de nuevos fármacos en ensayos clínicos
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.El tratamiento de la esclerosis sistémica (SSc) es un reto. Las nuevas terapias dirigidas, incluidos los biológicos y las moléculas pequeñas, son prometedoras para modular los mecanismos clave de la enfermedad y mejorar los resultados de los pacientes.
Área De La Ciencia
- Reumatología
- Inmunología
- Farmacología
Sus Antecedentes
- La esclerosis sistémica (SSc) presenta desafíos terapéuticos significativos.
- Los inmunosupresores convencionales ofrecen efectos modificadores de la enfermedad limitados en SSc.
- La falta de ensayos comparativos dificulta las opciones de tratamiento entre los inmunosupresores y los antifibróticos.
Objetivo Del Estudio
- Revisar los avances recientes en las terapias dirigidas para la SSc.
- Centrarse en nuevos productos biológicos y pequeñas moléculas dirigidas a mecanismos clave de SSc.
- Proporcionar información actualizada sobre las estrategias de tratamiento emergentes para la SSc.
Principales Métodos
- Búsqueda de literatura de ensayos clínicos desde enero de 2020 hasta abril de 2025.
- Las bases de datos buscadas son PubMed/MEDLINE, clinicaltrials.gov y euclinicaltrials.eu.
- Análisis detallado de 14 estudios seleccionados (ensayos, resúmenes, series de casos).
Principales Resultados
- El perfil molecular identifica endotipos inflamatorios y fibróticos distintos en el SSc.
- Los estudios de imágenes sugieren un subconjunto fibroinflamatorio susceptible a la terapia dirigida.
- Las terapias dirigidas emergentes ofrecen nuevas vías de tratamiento potenciales para la SSc.
Conclusiones
- Los ensayos clínicos recientes en SSc ofrecen esperanzas de mejores resultados para los pacientes.
- Los avances en la comprensión de los endotipos de SSc guían el desarrollo de terapias dirigidas.
- La investigación futura debe centrarse en las directrices específicas del paciente para el tratamiento de SSc.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...